Product Information
BUPRENORPHINE 8 MG TABLET SL is a generic product labeled by Major Pharmaceuticals, priced at $0.5714 per EA under NDC 00904715504. Its NADAC has been published 210 times since Sep 28, 2022.
FDA first approved this application on Oct 8, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
8 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904715504
Classification
Generic
Dosage Form
TABLET
Route
SUBLINGUAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078633FDA Approved
10/8/2009
TE Code
AB
On Market Since
10/8/2009
Pharmacological Classes
Price Statistics
The NADAC for BUPRENORPHINE 8 MG TABLET SL has been published 210 times since Sep 28, 2022, and over the history we have for it it has declined 27.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5714 per EA |
|---|---|
| All-time high | $0.9642 (Aug 16, 2023) |
| All-time low | $0.5567 (Apr 22, 2026) |
| 52-week high | $0.7127 |
| 52-week low | $0.5567 |
| Median price | $0.7497 |
| Average price | $0.7530 |
| Largest weekly change | +27.5% (Aug 21, 2024) |
| Weeks tracked | 210 |
| Tracking since | Sep 28, 2022 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Buprenorphine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Partial Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPRENORPHINE 8 MG TABLET SL?
The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE 8 MG TABLET SL, manufactured by Major Pharmaceuticals, is $0.5714 per EA (NDC 00904715504), effective Sep 30, 2026.
How has the price of BUPRENORPHINE 8 MG TABLET SL changed over time?
Over the history we have for it, the NADAC for BUPRENORPHINE 8 MG TABLET SL has declined 27.5%. It has been tracked across 210 weekly CMS publications since Sep 28, 2022.
What are the highest and lowest recorded NADAC prices for BUPRENORPHINE 8 MG TABLET SL?
Since Sep 28, 2022, the NADAC for BUPRENORPHINE 8 MG TABLET SL has ranged from a low of $0.5567 (Apr 22, 2026) to a high of $0.9642 (Aug 16, 2023), with a median of $0.7497 per EA.
Are there cheaper alternatives to BUPRENORPHINE 8 MG TABLET SL?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUPRENORPHINE 8 MG TABLET SL in a comparable dosage form, but none are currently priced below it.
Who manufactures BUPRENORPHINE 8 MG TABLET SL?
BUPRENORPHINE 8 MG TABLET SL (NDC 00904715504) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.